WallStSmart

Edwards Lifesciences Corp (EW)vsUnilever PLC ADR (UL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Unilever PLC ADR generates 732% more annual revenue ($50.50B vs $6.07B). UL leads profitability with a 18.8% profit margin vs 17.7%. UL appears more attractively valued with a PEG of 1.91. EW earns a higher WallStSmart Score of 55/100 (C).

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 2/9

UL

Buy

50

out of 100

Grade: C-

Growth: 2.0Profit: 8.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWSignificantly Overvalued (-544.4%)

Margin of Safety

-544.4%

Fair Value

$12.31

Current Price

$82.67

$70.36 premium

UndervaluedFair: $12.31Overvalued
ULSignificantly Overvalued (-268.2%)

Margin of Safety

-268.2%

Fair Value

$20.26

Current Price

$60.80

$40.54 premium

UndervaluedFair: $20.26Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

UL4 strengths · Avg: 8.8/10
Return on EquityProfitability
31.0%10/10

Every $100 of equity generates 31 in profit

Market CapQuality
$132.46B9/10

Large-cap with strong market position

Operating MarginProfitability
20.1%8/10

Strong operational efficiency at 20.1%

Free Cash FlowQuality
$5.48B8/10

Generating 5.5B in free cash flow

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.7x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-76.6%2/10

Earnings declined 76.6%

UL3 concerns · Avg: 2.7/10
PEG RatioValuation
1.914/10

Expensive relative to growth rate

Revenue GrowthGrowth
-3.2%2/10

Revenue declined 3.2%

EPS GrowthGrowth
-3.4%2/10

Earnings declined 3.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.

Bull Case : UL

The strongest argument for UL centers on Return on Equity, Market Cap, Operating Margin. Profitability is solid with margins at 18.8% and operating margin at 20.1%.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.

Bear Case : UL

The primary concerns for UL are PEG Ratio, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

EW profiles as a mature stock while UL is a declining play — different risk/reward profiles.

EW carries more volatility with a beta of 0.93 — expect wider price swings.

EW is growing revenue faster at 13.3% — sustainability is the question.

UL generates stronger free cash flow (5.5B), providing more financial flexibility.

Bottom Line

EW scores higher overall (55/100 vs 50/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Unilever PLC ADR

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

Unilever PLC is a fast moving consumer goods company in Asia, Africa, the Middle East, Turkey, Russia, Ukraine, Belarus, America and Europe. The company is headquartered in London, the United Kingdom.

Want to dig deeper into these stocks?